I am sure you are right Remus , Hardie , Dresser/Halliburton and all he others with exposure to asbestos litigation know all about Coramsine . When the remaining phase 1 trial results come in I dont think funding will present any problems . If Coramsine just exended life of mesothelioma patients by a few years it probably would not help those companies much but would still be a commercial success for Solbec . There is a report of SBP002 on the MARF site in the USA , which is a big mesothelioma support site , so I think everybody knows about it . It may come to market quickly through its action on mesothelioma , but the real money will be treating the more common cancers , where it appears to be very effective . Dont forget the Psoriasis trial and the vetinerary applications , which could also be farmed off . There are several avenues where cash could flow into Solbec .
SBP Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
